Treating gout - can hypouricemia produced by moderate doses of combined oral treatment give early treatment success? Preliminary observations

Nucleosides Nucleotides Nucleic Acids. 2022;41(12):1267-1278. doi: 10.1080/15257770.2022.2039394. Epub 2022 Mar 8.

Abstract

Six male patients with gout were treated with combined oral medication (febuxostat, 120 mg/d, and benzbromarone, 50 or 100 mg/d), aiming at a more rapid success of uric acid lowering treatment (ULT) compared to guideline suggestions. By combined oral medication in moderate dosage, the sUA was reduced to <2 mg/dl in all cases. We conclude that, by the treatment schedule outlined, the majority of patients with gout can be cured within 1 - 2 years, with uricase treatment being necessary very rarely only.

Keywords: Gout; hypouricemia; treatment.

MeSH terms

  • Allopurinol
  • Febuxostat / therapeutic use
  • Gout Suppressants* / adverse effects
  • Gout Suppressants* / therapeutic use
  • Gout* / complications
  • Gout* / drug therapy
  • Humans
  • Male
  • Treatment Outcome
  • Uric Acid

Substances

  • Gout Suppressants
  • Febuxostat
  • Uric Acid
  • Allopurinol